Objective:

To assess demographic, clinical, and laboratory characteristics, sustained virological response at 12 weeks (SVR12), and drug-related adverse events in chronic hepatitis C patients treated with direct-acting antivirals (DAAs), highlighting their significance for treatment efficacy.

Key Findings:

• The study included 233 patients with a diverse demographic and clinical profile, indicating a broad representation of chronic hepatitis C cases.
• Sustained virological response at 12 weeks (SVR12) was assessed, providing insights into treatment efficacy and its implications for patient management.
• Adverse events related to DAA therapy were documented, contributing to understanding treatment safety and informing clinical practice.

Interpretation:

The findings highlight the effectiveness of DAAs in achieving SVR12 in a real-world setting, particularly among diverse and high-risk populations, emphasizing the need for tailored treatment approaches.

Limitations:

• The study was retrospective and conducted at a single center, which may limit generalizability and the applicability of findings to broader populations.
• Exclusion of patients with incomplete data or certain comorbidities may introduce selection bias, potentially affecting the study's conclusions.

Conclusion:

This study provides valuable real-world insights into the treatment outcomes of chronic hepatitis C patients in Türkiye, emphasizing the importance of including diverse populations in research to enhance treatment strategies.